First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study
Journal of Cystic Fibrosis · 2025-05 · 24 (3) · 457-465
DOI: 10.1016/j.jcf.2025.03.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-05. Verfasst von Anne-Sophie Bonnel und 30 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Référence Maladies rares, Mucoviscidose et maladies apparentées. Hôpital Necker Enfants Malades. Assistance Publique Hôpitaux de Paris. Par…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Quinolones, Fetal Therapies. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: We aimed to build a cohort of Maternal-Cystic Fibrosis (CF) fetal dyads treated in utero with Variant Specific Therapy (VST), to assess the efficacy on Meconium Ileus (MI) and potential adverse effects of treatment. METHODS: Dyads were included if the foetus had a genetic diagnosis of CF and carried at least one variant responsive to VST. Standardized assessment included pre-VST Magnetic Resonance Imaging (MRI), repeated ultrasound (US), and VST drug concentrations in cord blood, maternal and infant plasma. RESULTS: We enrolled 13 dyads. One withdrew from the study. VST therapies (Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor(IVA) (ETI) n = 11, ivacaftor (IVA) n = 1) were administered to the pregnant women between 19 and 36 weeks' of gestation for a median[IQR] of 35[55] days, either as a curative indication of MI (n = 8) or as a tertiary prevention of fetal CF-related intestinal symptoms (n = 4). One foetus experienced increased bowel dilatation after ETI introduction. MRI revealed intestinal atresia. One dyad received only 2 doses. In the other 6 cases, resolution of MI was observed within 14[10] days of ETI. Fetal development and neonatal tolerance were excellent. Fecal elastase at birth was always below 200 ng/g even in the ETI breast-fed infant. Cord-to-maternal concentration yielded median ratios of 0.40 for ELX, 0.54 for IVA and 1.59 for TEZ. CONCLUSION: ETI administration from the third trimester of pregnancy enables MI resolution. Trans-placental transfer is high. Fetal tolerance at ETI initiation needs to be monitored by a standardized assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Référence Maladies rares, Mucoviscidose et maladies apparentées. Hôpital Necker Enfants Malades. Assistance Publique Hôpitaux de Paris. Paris. France; Cystic Fibrosis Center. Hôpital Mignot. Le Chesnay. France.
- Cystic Fibrosis Center. Centre Hospitalier Universitaire. Nantes, France.
- Cystic Fibrosis Center. Centre Hospitalier Universitaire. Rennes, France.
- Service de Gynéco-obstétrique. Hôpital Necker Enfants Malades. Assistance Publique Hôpitaux de Paris. Paris. France.
- Service d'Imagerie Pédiatrique. Hôpital Necker Enfants Malades. Assistance Publique Hôpitaux de Paris. France.
- U1343. Pharmacologie et évaluations thérapeutiques chez l'enfant et la femme enceinte. Inserm, Université Paris Cité. Paris. France; Service de Pharmacologie périnatale pédiatrique et adulte. Hôpital Cochin, Hôpital Eur…
Zitieren
APA
Bonnel, A. S., Bihouée, T., Ribault, M., Driessen, M., Grèvent, D., Foissac, F., Truong, N. H., Benhamida, M., Arnouat, B., Borghese, R., Chedevergne, F., Couderc-Kohen, L., da Silva, J., Grenet, D., Houdouin, V., Le, A., Marchal, S., Deneuville, E., Pouradier, D., …, & MODUL-CF study group (2025). First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study. Journal of Cystic Fibrosis, 24(3), 457-465. https://doi.org/10.1016/j.jcf.2025.03.009
Vancouver
Bonnel AS, Bihouée T, Ribault M, Driessen M, Grèvent D, Foissac F, et al. First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study. Journal of Cystic Fibrosis. 2025;24(3):457-465. doi:10.1016/j.jcf.2025.03.009
BibTeX
@article{Bonnel2025,
author = {Bonnel, Anne-Sophie and Bihouée, Tiphaine and Ribault, Mélanie and Driessen, Marine and Grèvent, David and Foissac, Frantz and Truong, Ngoc Hoa and Benhamida, Myriam and Arnouat, Baptiste and Borghese, Roxana and Chedevergne, Frédérique and Couderc-Kohen, Laure and da Silva, Jennifer and Grenet, Dominique and Houdouin, Véronique and Le, Anais and Marchal, Sarah and Deneuville, Eric and Pouradier, Delphine and Rousseau, Véronique and Treluyer, Jean-Marc and Francart, Arnaud and Steffann, Julie and Reix, Philippe and Benaboud, Sihem and Mamzer, Marie France and Ville, Yves and Martin, Clémence and Burgel, Pierre-Régis and Sermet-Gaudelus, Isabelle and MODUL-CF study group, MODUL-CF study group},
title = {First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {3},
pages = {457--465},
doi = {10.1016/j.jcf.2025.03.009}
}
EUVIMED